Raf-1 kinase inhibitor protein: Structure, function, regulation of cell signaling, and pivotal role in apoptosis

Advances in Cancer Research

Volumn 91, Issue , 2004, Pages 169-200

  Odabaei, Golaun ^a   Chatterjee, Devasis ^b   Jazirehi, Ali R ^a   Goodglick, Lee ^a   Yeung, Kam ^c   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CISPLATIN; DOXORUBICIN; G PROTEIN COUPLED RECEPTOR KINASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RAF PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL ACTIVITY; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXIC LYMPHOCYTE; DRUG TARGETING; ENZYME ACTIVITY; GENE THERAPY; HUMAN; IMMUNOTHERAPY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEOMICS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL;

EID: 4344607453     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(04)91005-6     Document Type: Article

References (75)

1. Ahn N.G. The MAP kinase cascade: Discovery of a new signal transduction pathway. Mol. Cell. Biochem. 127128:1993;201-209
2. Alas S., Bonavida B. Rituximab inactivates STAT3 activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrineparacrine loop and results in downregulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 61:2001;5137-5144
3. Ashkenazi A., Dixit V.M. Death receptors: Signaling and modulation. Science. 281:1998;1305-1308
4. Austen M., Luscher B., Luscher-Firlaf J.M. Characterization of the transcriptional regulator YY1: The bipartite transactivation domain is independent of interaction with the TATA box-binding protein, transcription factor IIB, TAFII55, or cAMP-responsive element-binding protein (CBP)-binding protein. J. Biol. Chem. 272:1997;1709-1717
5. Banfield M.J., Barker J.J., Perry A.C., Brady R.L. Function from structure? The crystal structure of human phosphatidylethanolamine-binding protein suggests a role in membrane signal transduction. Structure. 6:1998;1245-1254
6. Bernier I., Jolles P. Purification and characterization of a basic 23 kDa cytosolic protein from bovine brain. Biochim. Biophys. Acta. 790:1984;174-181
7. Bossy-Wetzel E., Green D.R. Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. J. Biol. Chem. 274:1999;17484-17490
8. Bruder J.T., Heidecher G., Rapp U.R. Serum, TPA and Ras-induced expression from Ap-1Cts-driven promoter require Raf-1 kinase. Genes Dev. 6:1992;545-556
9. Chatterjee D., Schmitz I., Krueger A., Yeung K., Kirchhoff S., Krammer P.H., Peter M.E., Wyche J.H., Pantazis P. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP (short). Cancer Res. 61:2001;7148-7154
10. Chatterjee D., Roy R., Braastad C., Mott S., Sun Y., Mukhopadhay A., Aggarwal B., Darnowski J., Pantazis P., Wyche J.H., Sedivy J.M., Yeung K. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. 2004;. (Submitted.)
11. Coiffier B. Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev. 17:2003;25-31
12. Corbit K.C., Trakul N., Eves E.M., Diaz B., Marshall M., Rosner M.R. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol. Chem. 278:2003;13061-13068
13. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16:1988;10881-10890
14. Demidem A., Lam T., Alas S., Hariharan K., Hanna N., Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12:1997;177
15. Dong C., Davis R.J., Flavell R.A. MAP kinases in the immune response. Annu. Rev. Immunol. 20:2002;55-72
16. Emmanouilides C., Jazirehi A.R., Bonavida B. Rituximab-mediated sensitization of non-Hodgkin's lymphoma (NHL) B-cells to cytotoxicity induced by paclitaxel, gemcitabine and vinorelbine. Cancer Biother. Radiopharm. 17:2002;621-630
17. Frayne J., Ingram C., Love S., Hall L. Localisation of phosphotidylethanolamine-binding protein in the brain and other tissues of the rat. Cell Tissue Res. 298:1999;415-423
18. Fu Z., Dozmorov I., Keller E. Osteoblasts produce soluble factors that induced a gene expression pattern in non metastatic prostate cells, similar to that found in bone metastatic cancer cells. Prostate. 51:2002;10-20
19. Fu Z., Smith P.C., Zhang L., Rubin M.A., Dunn R.L., Yao Z., Keller E.T. Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 95:2003;878
20. Garban H., Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: A pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J. Immunol. 167:2001;75-81
21. Genot E., Cantrell D.A. Ras regulation and function in lymphocytes. Curr. Opin. Immunol. 12:2000;289-294
22. Ghosh S., May M.J., Kopp E.B. NF-κB and Rel proteins: Evolutionary conserved mediators of immune responses. Annu. Rev. Immunol. 16:1998;225-260
23. Ham J., Eilers A., Whitfield J., Neame S.J., Shah B. c-Jun and the transcriptional control of neuronal apoptosis. Biochem. Pharmacol. 60:2000;1015-1021
24. Hengst U., Albrecht H., Hess D., Monard D. The phosphatidyl ethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors. J. Biol. Chem. 276:2001;535-540
25. Hickox D.M., Gibbs G., Morrison J.R., Sebire K., Edgar K., Keah H.H., Alter K., Loveland K.L., Hearn M.T., de Kretser D.M., O'Bryan M.K. Identification of a novel testis-specific member of the phosphatidylethanolamine binding protein family, PEBP-2. Biol. Reprod. 67:2002;917-927
26. Huerta-Yepez S., Vega M., Jazirehi A., Garban H., Hongo F., Cheng G., Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappaB and inhibition of Bcl-(xL) expression. Oncogene. 2004;. [Epub ahead of print].
27. Huhn D., Von Schilling C., Wilhelm M., Ho A., Hallek M., Kuse R., Knauf W., Riedel U., Hinke A., Srock S., Serke S., Peschel C., Emmerich B. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 98:2001;1326-1331
28. Jazirehi A.R., Emmanoluides C., Bonavida B. Rituximab sensitizes non-Hodgkin's lymphoma (NHL) B cell lines to Taxol-mediated cytotoxicity and synergy is achieved in both apoptosis and necrosis [abstract 563]. Blood. 96:2000;131a
29. L [abstract 4610]. Proc. Am. Assoc. Cancer Res. 44:2003a;1057
30. L and Apaf-1 expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther. 2:2003b;1183-1193
31. L expression. 2004a;. (Submitted.)
32. L expression. 2004b;. (Submitted.)
33. Karin M., Cao Y., Greten F.R., Li Z.-W. NF-κB in cancer: From innocent bystander to major culprit. Nat. Rev. 2:2002;301
34. Klaus S.J., Sidorenko S.P., Clark E.A. CD45 ligation induces programmed cell death in T and B lymphocytes. J. Immunol. 156:1996;2743-2753
35. Kauffman E.C., Robinson V.L., Stadler W.M., Sokoloff M.H., Rinker-Schaeffer C.W. Metastasis suppression: The evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 169:2003;1122-1133
36. Krikun G., Lockwood C.J. Steroid hormones, endometrial gene regulation and the Sp1 family of proteins. J. Soc. Gynecol. Invest. 9:2002;329-334
37. Kroslak T., Koch T., Kahl E., Hollt V. Human phosphatidylethanolamine- binding protein facilitates heterotrimeric G protein-dependent signaling. J. Biol. Chem. 276:2001;39772-39778
38. Krupuilk J.G., Benovic J.L. The role of receptor kinases and arrestins in G-protein coupled receptor regulation. Am. Rev. Pharmacol. Toxicol. 38:1998;289-319
39. Lefkowitz R.J., Pitcher J., Krueger K., Daak Y. Mechanisms of β-adrenergic receptor desensitization and resensitization. Adv. Pharmacol. 42:1998;416-420
40. Li X., Stark G.R. NF-κB-dependent signaling pathways. Exp. Hematol. 30:2002;285-296
41. Lorenz K., Lohse M.J., Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature. 426:2003;574-579
42. Maki M., Matsukawa N., Yuasa H., Otsuka Y., Yamamoto T., Akatsu H., Okamoto To., Ueda R., Ojika K. Decreased expression of hippocampal cholinergic neurostimulating peptide precurson protein mRNA in the hippocampus in Alzheimer disease. J. Neuropathol. Exp. Neurol. 61:2002;176-185
43. Marais R., Marshall C.J. Control of the ERK MAP kinase cascade by Ras and Raf. [Review: Marks, D. B., Marks, A. D., and Smith, C. M. (1996). "Basic Medical Biochemistry: A Clinical Approach." Lippincott Williams & Wilkins, Philadelphia, PA.] Cancer Surv. 27:1996;101-125
44. Marco E., Garcia-Nieto R., Gago F. Assessment by molecular dynamics simulations of the structural determinants of DNA-binding specificity for transcription factor Sp1. J. Mol. Biol. 328:2003;9-32
45. Mimida N., Goto K., Kabayashi Y., Araki T., Ahn J.H., Weigel D., Murata M., Motoyoshi F., Sakamoto W. Functional divergence of the TFL1-like gene family in Arabidopsis revealed by characterization of a novel homologue. Genes Cells. 6:2001;327-336
46. Moodie S.A., Willumsen B.M., Weber M.J., Wolfman A. Complexes of Ras:GTP with Raf-1 and mitogen-activated protein kinase kinase. Science. 260:1993;1658-1661
47. Morrison D.K., Cutler R.E. The complexity of Raf-1 regulation [review]. Curr. Opin. Cell Biol. 9:1997;174-179
48. Ng C.-P., Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: Two complementary signals to overcome cross-resistance. Adv. Cancer Res. 85:2002;145-174
49. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:1994;435-445
50. Rothwarf D.M., Karin M. The NF-κB activation pathway: A paradigm in information transfer from membrane to nucleus [review]. Sci. STKE. 5:1999;RE1
51. Ryu H., Lee H., Zaman K., Kubilis J., Ferrante R., Ross B.D., Neve R., Ratan R.R. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J. Neurosci. 23:2003;3597-3606
52. Sakahira H., Enari M., Ohsawa Y., Uchiyama Y., Nagata S. Apoptotic nuclear morphological change without DNA fragmentation. Curr. Biol. 9:1999;543-546
53. Scaffidi C., Fluda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1Fas) signalling pathways. EMBO J. 17:1998;1675-1687
54. Schoentgen F., Jolles P. From structure to function: Possible biological roles of a new wide-spread protein family binding hydrophobic ligands and displaying a nucleotide binding site. FEBS Lett. 369:1995;22-26
55. Schoentgen F., Saccoccio F., Jolles J., Bernier I., Jolles P. Complete amino acid sequence of basic 21-kDa protein from bovine brain cytosol. Eur. J. Biochem. 166:1987;333-338
56. Schug J., Overton G.C. TESS: Transcription Element Search Software on the WWW. Technical report CBIL-TR-1997-1001-v0.0. URL: http:www.cbil.upenn.edutess: 1997
57. Seddiqi N., Segretain D., Bucquoy S., Jegou B., Jolles P., Schoentgen F. Characterization and localization of the rat, mouse, and human testicular phosphatidylethanolamine binding protein. Experientia. 52:1996;101-110
58. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4:2002;E131-E136
59. Shresta S., Pham C.T., Thomas D.A., Graubert T.A., Ley T.J. How do cytotoxic lymphocytes kill their targets? [review] Curr. Opin. Immunol. 10:1998;581-587
60. Simister P.C., Banfield M.J., Brady R.L. The crystal structure of PEBP-2, a homologue of the PEBPRKIP family. Acta Crystallogr. D. 58:2002;1077-1080
61. Slupsky J.R., Quitterer U., Weber C.K., Gierschik P., Lohse M.J., Rapp U.R. Binding of Gβγ subunits to cRaf1 downregulates G-protein-coupled receptor signalling. Curr. Biol. 9:1999;971-974
62. Steeg P.S., Ouatas T., Halverson D., Palmieri D., Salerno M. Metastasis suppressor genes: Basic biology and potential clinical use. Clin. Breast Cancer. 4:2003;51-62
63. Thompson C.B. Apoptosis in the pathogenesis and treatment of diseases. Science. 267:1995;1456
64. Thornberry N.A., Lazebnik Y. Caspases: Enemies within. Science. 281:1998;1312-1316
65. Vallee B.S., Tauc P., Brochon J.C., Maget-Dana R., Lelievre D., Metz-Boutigue M.H., Bureaud N., Schoentgen F. Behavior of bovine phosphatidyl ethanolamine-binding protein with model membranes: Evidence of affinity for negatively charged membranes. Eur. J. Biochem. 268:2001;5831-5841
66. Vallee B., Teyssier C., Maget-Dana R., Ramstein J., Bureaud N., Schoentgen F. Stability and physicochemical properties of the bovine brain phosphatidylethanolamine-binding protein. Eur. J. Biochem. 266:1999;40-52
67. Vega M.I., Huerta-Yepez S., Garban H., Jazirehi A., Emmanouilides C., Bonavida B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance. Oncogene. 23:2004;3530-3540
68. 2-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell. Biol. 23:2003;2871-2882
69. Verrecchia F., Rossert J., Nayvuekm A. Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: Implications for the treatment of tissue fibrosis. J. Invest. Dermatol. 116:2001;755-763
70. Welsh D.R., Hunter T.W. A new member of the growing family of metastasis suppressors identified in prostate cancer. J. Natl. Cancer Inst. 95:2003;839-841
71. Whitmarsh A.J., Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74:1996;589-607
72. Wisdom R. AP-1: One switch for many signals. Exp. Cell Res. 253:1992;180-185
73. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F., Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M., Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signaling by RKIP. Nature. 401:1999;173-177
74. Yeung K., Janosch P., McFerran B., Rose D.W., Mischak H., Sedivy J.M., Kolch W. Mechanism of suppression of the RafMEKextracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein. Mol. Cell. Biol. 20:2000;3079-3085
75. Yeung K.C., Rose D.W., Dhillon A.S., Yaros D., Gustafsson M., Chatterjee D., McFerran B., Wyche J., Kolch W., Sedivy J.M. Raf kinase inhibitor protein interacts with NF-κB-inducing kinase and TAK1 and inhibits NF-κB activation. Mol. Cell. Biol. 21:2001;207-217